In situ Hybridization Market by Technique (FISH, CISH), Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic And Research Institutions) - Global Forecast to 2021
Get in-depth analysis of the COVID-19 impact on the In situ Hybridization Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the In situ Hybridization Market
Request For Special Pricing[194 Pages Report] The global ISH market size is projected to reach USD 739.9 million by 2021 from USD 557.1 million in 2016, at a CAGR of 5.8% during the forecast period.
By application, the cancer diagnosis segment is expected to account for the largest share of the global ISH market during forecast period
The large share of the cancer diagnosis segment can be attributed to the rising prevalence of cancer, coupled with increasing adoption of FISH in cancer diagnosis.
By technique, the FISH segment is expected to account for the larger share during the forecast period
The large share of the FISH technique segment can be attributed to its various features such as high resolution and rising adoption in research activities and laboratories to diagnose cancer, chromosomal abnormalities, and infectious diseases.
By geography, Asia Pacific (APAC) regional market to register fastest growth during the forecast period
Asia is the fastest-growing regional market owing to factors such as the growing presence of international companies in China and India, rising prevalence of cancer in this region, growing number of hospitals and diagnostic laboratories, and greater government initiatives in Australia
Market Dynamics
Driver: Rising incidence and prevalence of cancer
Globally, there has been a significant increase in diagnosis of people suffering from cancer. The rising prevalence of cancer can be attributed to a number of factors, such as increasing tobacco consumption in selected markets, changes in lifestyle, recurrent genetic abnormalities, and infectious diseases such as Hepatitis B and C. In various countries across the globe, people are adopting a more sedentary lifestyle, which is characterized by a high-calorie diet (that is rich in fat, refined carbohydrates, and animal protein) and low physical activity.
Restraint: Availability of high-throughput techniques
Traditional studies used FISH to analyze chromosomal abnormalities such as rearrangements, large deletions, and duplications. However, this method is limited by its low resolution or narrow target range. Due to recent advancements in high-throughput technologies, researchers are using genetic tools to overcome these limitations as these tools offer wide genome coverage with a higher resolution.
Opportunity: Companion diagnostics for cancer treatment
Companion diagnostic products demonstrate significant potential to improve the diagnosis and treatment of cancer. FISH-based biomarkers play a significant role in the development of companion diagnostics because of their ability to simultaneously evaluate morphology and gene amplification. The market for companion diagnostics is steadily growing, as personalized medicine improves patient care and assists in managing healthcare costs. Moreover, companion diagnostics enables patients to receive targeted treatments, particularly in the treatment of cancer.
Scope of the Report
|
Report Metric |
Details |
|
Market size available for years |
2014–2021 |
|
Base year considered |
2015 |
|
Forecast period |
2016–2021 |
|
Forecast units |
USD million |
|
Segments covered |
Technique, Application, End User, and Region |
|
Geographies covered |
North America, APAC, Europe, and RoW |
|
Companies covered |
Abbott Laboratories, Inc. (US), Roche (Switzerland), Leica Biosystems Nussloch GmbH (Germany), and Agilent Technologies (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), PerkinElmer, Inc. (US), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (US), ACD (US), and Bio SB Inc. (US). |
The research report categorizes the In situ Hybridization Market to forecast the revenues and analyze the trends in each of the following sub-segments:
In situ Hybridization Market, by Technique
- Fluorescence In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization
In situ Hybridization Market, by Application
- Cancer Diagnosis
- Immunology
- Neuroscience
- Cytology
- Infectious Diseases
In situ Hybridization Market, by End User
- Molecular Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutions
In situ Hybridization Market, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Key Market Players
Abbott Laboratories, Inc. (US), Roche (Switzerland), Leica Biosystems Nussloch GmbH (Germany), and Agilent Technologies (US)
Recent Developments
- Abbott laboratories added Alinity, a harmonized family of next-generation systems, to its product portfolio.
- Roche established a new diagnostic manufacturing facility in China.
- Agilent Technologies entered into an agreement with ASI (U.S.) to jointly market ASI’s most advanced GenASIs imaging platforms and Agilent's FISH products and solutions.
- Leica Biosystems collaborated with ACD (U.S.) to develop and commercialize tissue-based diagnostic tests based on ACD's RNAscope ISH assays on Leica Biosystems BOND clinical advanced staining instruments.
- Abbott collaborated with Janssen Biotech, Inc. (U.S.) and Pharmacyclics, Inc. (U.S.) to explore the use of Abbott's proprietary FISH technology.
Critical questions the report answers:
- Where will all these developments take the In situ Hybridization market in the long term?
- What are the upcoming trends for the In situ Hybridization market?
- Which segment in the In situ Hybridization market provides the most opportunity for growth?
- Who are the leading vendors operating in this In situ Hybridization market?
- What are the opportunities for new market entrants in the In situ Hybridization market?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Key Industry Insights
2.3 Key Data From Primary Sources
2.4 Key Insights From Primary Sources
2.5 Market Size Estimation Methodology
2.5.1 Research Design
2.6 Market Data Validation and Triangulation
2.7 Assumptions for the Study
3 Executive Summary
4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restaints/Challenges
4.2.3 Opportunities
5 By Technique
5.1 Introduction
5.2 Fluorescence In Situ Hybridization Market (FISH)
5.2.1 DNA-FISH
5.2.2 RNA-FISH
5.3 Chromogenic In Situ Hybridization Market (CISH)
6 By Application
6.1 Introduction
6.2 Cancer Diagnosis
6.3 Immunology
6.4 Neuroscience
6.5 Cytology
6.6 Infectious Diseases
7 By End-User
7.1 Introduction
7.2 Molecular Diagnostic Laboratories
7.3 Pharmaceutical & Biotechnology Companies
7.4 Contract Research Organizations (CROS)
7.5 Academic & Research Institutions
8 By Region
8.1 Introduction
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 EU5- (U.K, Germany, France, Spain & Italy)
8.3.2 Rest of Europe (RoE)
8.4 Asia-Pacific
8.5 Rest of the World
(Consolidated Market Numbers for Latin America, Middle-East and Africa Will Be Provided)
9 Competitive Landscape
9.1 Overview
9.2 Competitive Situation and Trends
9.2.1 Approvals
9.2.2 Product Deployments
9.2.3 New Product Launches
9.2.4 Others (If Any)
10 Company Profiles
10.1 Introduction
10.2 ABBott Laboratories, Inc.
10.2.1 Business Overview
10.2.2 Financial Overview
10.2.3 Product Offerings
10.2.4 Recent Developments
10.3 F.Hoffmann-La Roche Ltd.
10.4 Thermofisher Scientific, Inc.
10.5 Merck KGaA
10.6 Agilent Technologies, Inc.
10.7 Perkin Elmer, Inc.
10.8 Danaher Corporation / Leica Biosystems Nussloch GmbH
10.9 Exiqon A/S
10.10 Biogenex Laboratories, Inc.
10.11 Advanced Cell Diagnostics, Inc
10.12 Bio Sb, Inc.
List of Tables (60 Tables)
Table 1 Global In Situ Hybridization Market, By Region/Country, 2016 (USD Million)
Table 2 Global Market Size, By Technique, 2014–2021 (USD Million)
Table 3 Global FISH Market Size, By Region, 2014–2021 (USD Million)
Table 4 North America: FISH Market Size, By Country, 2014–2021 (USD Million)
Table 5 Europe: FISH Market Size, By Country, 2014–2021 (USD Million)
Table 6 Global DNA-FISH Market Size, By Region, 2014–2021 (USD Million)
Table 7 North America: DNA-FISH Market Size, By Country, 2014–2021 (USD Million)
Table 8 Europe: DNA-FISH Market Size, By Country, 2014–2021 (USD Million)
Table 9 Global RNA-FISH Market Size, By Region, 2014–2021 (USD Million)
Table 10 North America: RNA-FISH Market Size, By Country, 2014–2021 (USD Million)
Table 11 Europe: RNA-FISH Market Size, By Country, 2014–2021 (USD Million)
Table 12 Global CISH Market Size, By Region, 2014–2021 (USD Million)
Table 13 North America: CISH Market Size, By Country, 2014–2021 (USD Million)
Table 14 Europe: CISH Market Size, By Country, 2014–2021 (USD Million)
Table 15 Global In Situ Hybridization Market Size, By Application, 2014–2021 (USD Million)
Table 16 Global Market Size for Cancer Diagnosis, By Country/Region, 2014–2021 (USD Million)
Table 17 Global Market Size for Cytology, By Country/Region, 2014–2021 (USD Million)
Table 18 Global Market Size for Neuroscience, By Country/Region, 2014–2021 (USD Million)
Table 19 Global Market Size for Immunology, By Country/Region, 2014–2021 (USD Million)
Table 20 Global Market Size for Infectious Diseases, By Country/Region, 2014–2021 (USD Million)
Table 21 Global Market Size, By End User, 2014–2021 (USD Million)
Table 22 Global Market Size for Molecular Diagnostic Laboratories, By Region, 2014–2021 (USD Million)
Table 23 North America: Market Size for Molecular Diagnostic Laboratories, By Country, 2014–2021 (USD Million)
Table 24 Europe: Market Size for Molecular Diagnostic Laboratories, By Country, 2014–2021 (USD Million)
Table 25 Global In Situ Hybridization Market Size for Academic & Research Institutes, By Region, 2014–2021 (USD Million)
Table 26 North America: Market Size for Academic & Research Institutes, By Country, 2014 – 2021 (USD Million)
Table 27 Europe: Market Size for Academic & Research Institutes, By Country, 2014–2021 (USD Million)
Table 28 Global Market Size for Contract Research Organizations, By Region, 2014 – 2021 (USD Million)
Table 29 North America: Market Size for Contract Research Organizations, By Country, 2014 – 2021 (USD Million)
Table 30 Europe: Market Size for Contract Research Organizations, By Country, 2014–2021 (USD Million)
Table 31 Global Market Size for Pharmaceutical & Biotechnology Companies, By Region, 2014–2021 (USD Million)
Table 32 North America: Market Size for Pharmaceutical & Biotechnology Companies, By Country, 2014–2021 (USD Million)
Table 33 Europe: Market Size for Pharmaceutical & Biotechnology Companies, By Country, 2014–2021 (USD Million)
Table 34 Global Market Size, By Region, 2014–2021 (USD Million)
Table 35 North America: In Situ Hybridization Market Size, By Country, 2014–2021 (USD Million)
Table 36 North America: Market Size, By Technique, 2014–2021 (USD Million)
Table 37 North America: Market Size, By Application, 2014–2021 (USD Million)
Table 38 North America: Market Size, By End User, 2014–2021 (USD Million)
Table 39 U.S.: In Situ Hybridization Market Size, By Technique, 2014–2021 (USD Million)
Table 40 U.S.: Market Size, By Application, 2014–2021 (USD Million)
Table 41 U.S.: Market Size, By End User, 2014–2021 (USD Million)
Table 42 Canada: Market Size, By Technique, 2014–2021 (USD Million)
Table 43 Canada: Market Size, By Application, 2014–2021 (USD Million)
Table 44 Canada: Market Size, By End User, 2014–2021 (USD Million)
Table 45 Europe: In Situ Hybridization Market Size, By Country, 2014–2021 (USD Million)
Table 46 Europe: Market Size, By Technique, 2014–2021 (USD Million)
Table 47 Europe: Market Size, By Application, 2014–2021 (USD Million)
Table 48 Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 49 EU-5: Market Size, By Technique, 2014–2021 (USD Million)
Table 50 EU-5: Market Size, By Application, 2014–2021 (USD Million)
Table 51 EU-5: Market Size, By End User, 2014–2021 (USD Million)
Table 52 Rest of Europe: In Situ Hybridization Market Size, By Technique, 2014–2021 (USD Million)
Table 53 Rest of Europe: Market Size, By Application, 2014–2021 (USD Million)
Table 54 Rest of Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 55 Asia-Pacific: Market Size, By Technique, 2014–2021 (USD Million)
Table 56 Asia-Pacific: Market Size, By Application, 2014–2021 (USD Million)
Table 57 Asia-Pacific: Market Size, By End User, 2014–2021 (USD Million)
Table 58 RoW: In Situ Hybridization Market Size, By Technique, 2014–2021 (USD Million)
Table 59 RoW: Market Size, By Application, 2014–2021 (USD Million)
Table 60 RoW: Market Size, By End User, 2014–2021 (USD Million)
List of Figures (26 Figure)
Figure 1 Market Size Estimation - USD Value
Figure 2 Market Sizing – (USD Value Analysis)
Figure 3 Competitive Assessment
Figure 4 Research Design
Figure 5 Data Triangulation
Figure 6 Global In Situ Hybridization Market, By Technique, 2016 (USD Million)
Figure 7 Global Market, By Application, 2016 (USD Million)
Figure 8 Global Market, By End User, 2016 (USD Million)
Figure 9 Market Overview
Figure 10 Global Market Segmentation, By Technique
Figure 11 The FISH Technique Segment is Expected to Dominate the Global Market in 2016
Figure 12 In Situ Hybridization Market Segmentation, By Application
Figure 13 Cancer Diagnosis Segment to Dominate the Market During the Forecast Period
Figure 14 Timeline of FDA Approvals for Key FISH-Based Companion Diagnostics in Oncology
Figure 15 Global Market Segmentation, By End User
Figure 16 Molecular Diagnostic Laboratories Dominate the Global Market, By End User (2016)
Figure 17 Market Share Analysis
Figure 18 Share of Key Strategies (2013–2016)
Figure 19 Agreements, Collaborations, and Partnerships (2013–2016)
Figure 20 Product Launches (2013–2016)
Figure 21 Expansions (2013–2016)
Figure 22 Acquisitions (2013–2016)
Figure 23 Other Strategies (2013–2016)
Figure 24 Route to Growth: Organic vs Inorganic Strategies
Figure 25 Organic Growth Strategies
Figure 26 Inorganic Growth Strategies
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the In situ Hybridization Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in In situ Hybridization Market